John Smither Sells 12,000 Shares of Genelux (NASDAQ:GNLX) Stock

Genelux Corporation (NASDAQ:GNLX) Director John Smither sold 12,000 shares of Genelux stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total transaction of $34,920.00. Following the transaction, the director directly owned 91,403 shares of the company’s stock, valued at $265,982.73. This represents a 11.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Genelux Price Performance

NASDAQ:GNLX opened at $2.99 on Friday. The firm has a market cap of $134.07 million, a PE ratio of -3.52 and a beta of 0.58. Genelux Corporation has a 12 month low of $2.29 and a 12 month high of $8.53. The company’s 50-day moving average price is $2.90 and its two-hundred day moving average price is $2.93.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.02). On average, research analysts expect that Genelux Corporation will post -0.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Genelux

Institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning raised its holdings in Genelux by 4.7% during the 3rd quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after purchasing an additional 2,084 shares during the last quarter. Raymond James Financial Inc. lifted its holdings in Genelux by 22.6% in the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after buying an additional 5,333 shares during the period. Geode Capital Management LLC boosted its stake in Genelux by 1.8% in the second quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock valued at $915,000 after acquiring an additional 5,596 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in Genelux during the 4th quarter worth $48,000. Finally, Squarepoint Ops LLC acquired a new stake in Genelux during the 4th quarter worth $52,000. Institutional investors own 37.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on GNLX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Tuesday, April 21st. Benchmark decreased their target price on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a report on Friday, March 20th. Finally, Wall Street Zen lowered Genelux from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.